|
| PRIONIX Target Product ProfilesComparison of Key Attributes |
|
| |
| | As an anti-inflammatory agent |
| | As a disease-modifying anti-rheumatic agent |
|
| Indication |  |
|
|
|
|
For symptomatic relief of the inflammation of rheumatoid arthritis |
|
|
|
| |
|
|
|
|
For treatment of rheumatoid arthritis to reduce symptoms and joint erosion |
|
|
|
|
| Efficacy |
| Symptomatic reliefreduce joint inflammation pain, stiffness, and fatigue | |
|
|
|
|
Efficacy at least as good as NSAIDs |
|
|
|
|
|
|
|
|
Speed of onset within 4 weeks |
|
|
|
| N/A |
| Joint erosion | N/A | |
|
|
|
|
Radiological evidence of joint protection; onset 612 months |
|
|
|
|
| Safety and tolerance |
| General | |
|
|
|
|
Good ADRs profile which supports broad use |
|
|
|
| |
|
|
|
|
ADR profile does not limit to 2° line therapy |
|
|
|
|
|
|
|
|
|
Gastrointestinal
-upper and lower GI symptoms
-gastric erosions |
|
|
|
| |
|
|
|
|
Incidence of GI intolerance significantly better than NSAIDs (<5%) |
|
|
|
| |
| Drug interactions | N/A | |
|
|
|
|
Can be prescribed with commonly used NSAIDs |
|
|
|
|
| Dose regimen | Oral tid | Oral tid (want)
Intramuscular (must) |